TerminatedPhase 2NCT03124459
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Principal Investigator
- Jay Backstrom, MDAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Intervention
- ACE-083(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (16)
- University of California-Irvine, Orange, California, United States
- University of Colorado, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- University of Kansas Medical Center - Neurology Department, Kansas City, Kansas, United States
- University of Minnesota, Neurology Department, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Columbia University, New York, New York, United States
- University of Rochester Medical Center, Neurology, Rochester, New York, United States
- Carolinas Healthcare System Neurosciences Institute, Charlotte, North Carolina, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- University of Vermont, Burlington, Vermont, United States
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03124459 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT01193088Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2University of Iowa
- RECRUITINGNCT01193075Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and OthersMichael Shy
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 →